Peptide Library

Human study PLS-00045

Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.

Cross-sectional study · 150 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.primary · Kidney & blood pressure research · 2026-05-21 · PMID 42166398 · DOI

Design and participants

Design
Cross-sectional study
Population
Kidney transplant recipients (118) and age-matched controls (32)
Conditions
Kidney transplantation, Cardiovascular disease
Setting
Observational cohort; kidney transplant recipients followed for a median of 29.2 months
Planned enrollment (registry)
Not reported
Enrolled
150
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Elevated serum nardilysin and MOTS-c levels in kidney transplant recipients may reflect altered metabolic and inflammatory pathways. The inverse link between nardilysin and prevalent cardiovascular disease needs longitudinal study.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was measured only as an endogenous circulating biomarker and never given as an intervention.
    • abstract only: Only a truncated abstract is available; the results section is cut off in the record.
    • inappropriate population: Kidney transplant recipients differ from the claim populations, such as adults with obesity or diabetes.
    • inappropriate endpoint: MOTS-c was measured only as an endogenous circulating marker. It was not given as an intervention, so the study cannot show treatment effects or safety.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 42166398, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 42166398, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 42166398, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 42166398, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).